联合用药治疗矽肺患者的血清铜蓝蛋白含量变化  

Changes in serum ceruloplasmin(Cp) levels of silicotic patients treated with combined tetrandrine and hydroxy piperaquinoline phosphate

作　　者：刘秉慈[1] 尤宝荣[1] 缪庆[1] 徐茗[1] 王海华[1] 袁伯华[1] 

机构地区：[1]北京中国预防医学科学院劳动卫生与职业病研究所,100050

出　　处：《中华劳动卫生职业病杂志》2001年第1期14-16,共3页Chinese Journal of Industrial Hygiene and Occupational Diseases

基　　金：国家科学技术委员会"九五"科技攻关项目!(96 90 6 0 4 10 )

摘　　要：目的　观察联合用药对矽肺患者血清铜蓝蛋白 (Cp)含量的影响。方法　采用ELISA法测定汉防己甲素 (汉甲素 )及磷酸羟基哌喹 (羟哌 )联合用药的矽肺患者血清Cp含量。“八五”攻关课题“矽肺治疗措施及效果评价研究”(简称“八五”)中已经过治疗的病例 10 2人 ,分为大剂量组、小剂量组、停药组及对照组 ;“九五”攻关课题“联合用药治疗矽肺效果及综合评价方法研究”(简称“九五”)中新选早期矽肺病例32人 ,分为大剂量组和对照组。于第二、四、六疗程后取血测定血清中Cp含量。结果　 (1)“八五”病例第二疗程后 ,小剂量及大剂量组患者血清Cp含量即比疗前和同期对照组下降 ;至第四、六疗程后 ,两组血清Cp水平均较疗前及停药组明显下降 ;第六疗程后 ,大剂量组血清Cp水平明显低于小剂量组。经 6个疗程大剂量治疗后 ,矽肺患者血清Cp水平由疗前的 (3.78± 0 .18)U/μl下降到(3.40± 0 .2 1)U/μl,差异有显著性 (P <0 .0 5 )。 (2 )“九五”病例第二疗程后 ,血清Cp水平由疗前的 (3.5 3± 0 .32 )U/μl下降至 (3.31±0 .2 8)U/μl,差异有显著性 (P <0 .0 5 )。至第四及第六疗程 ,血清Cp含量又有下降 ,不仅低于疗前水平 ,而且低于对照组 ,血清Cp水平降低程度与用药剂量及时间成正比。结论　汉甲素及羟哌联合用药能?Objective To observe the effects of combined tetrandrine(TD) and hydroxy piperaquinoline phosphate(HOPQ) on serum ceruloplasmin(Cp) levels of silicotic patients. Methods ELISA method was used to detect Cp levels.134 silicotic patients were divided into two groups.The first group(102 patients) had been treated during the National Projects of the 8 th Five year Plan.The second group included 32 early stage silicotic patients without any treatment before.The first group was divided into four subgroups:high dosage,low dosage,stop treatment and control.The second group was divided into two subgroups:high dosage and control.All the patients were treated during the whole period that contained six courses within 2 years. Results (1)In the first group,Cp levels in the high dosage and low dosage subgroup were significantly different from those before treatment and in control subgroup after the second course.After the fourth and sixth courses,Cp levels were significantly lower than those before treatment and in stop treatment subgroup.Cp levels in high dosage subgroup decreased from (3.78±0.18)U/μl to (3.40± 0.21)U/μl ( P <0.05) six courses later,which was less than that in low dosage subgroup.(2)In the second group,after the second course,Cp levels in high dosage subgroup decreased from (3.53±0.32)U/μl to (3.31±0.28)U/μl( P <0.05).After the fourth and sixth courses,Cp levels were significantly lower than that before treatment and that in control subgroup.The degree of changes was in proportion to the dosages and time courses. Conclusion Combined treatment with TD+HOPQ could inhibit the rise of serum Cp level which is of certain value in evaluation of therapeutic effect of antisilicotic drugs.Since ELISA method less depends on the storage and transportation conditions of serum,it is suggested to be used in the future on the spot and clinical studies on silicosis.

关 键 词：血清铜蓝蛋白 ELISA 矽肺 药物疗法 联合用药 汉防己甲素 磷酸羟基哌喹 治疗 

分 类 号：R135.2[医药卫生—劳动卫生]